spacer
spacer

PDBsum entry 5iee

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase PDB id
5iee

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
857 a.a.
88 a.a.
Ligands
NAG-NAG
PG4 ×3
P6G ×4
EDO ×6
FMT ×10
NOJ
Metals
_CA ×2
Waters ×950
PDB id:
5iee
Name: Hydrolase
Title: Murine endoplasmic reticulum alpha-glucosidase ii with 1- deoxynojirimycin
Structure: Neutral alpha-glucosidase ab. Chain: a. Synonym: alpha-glucosidase 2,glucosidase ii subunit alpha. Engineered: yes. Other_details: this chain contains all of the residues from the mature q8bhn3 isoform 2 (i.E. No signal peptide and starts at residue 33) but has been trypsinised so that there are two gaps in the sequence between: 186-243 and 351-369 (inclusive). Glucosidase 2 subunit beta.
Source: Mus musculus. Mouse. Organism_taxid: 10090. Gene: ganab, g2an, kiaa0088. Expressed in: homo sapiens. Expression_system_taxid: 9606. Expression_system_cell_line: hek 293-f. Expression_system_organ: kidney. Expression_system_cell: endothelial.
Resolution:
1.92Å     R-factor:   0.166     R-free:   0.196
Authors: A.T.Caputo,P.Roversi,D.S.Alonzi,J.L.Kiappes,N.Zitzmann
Key ref: A.T.Caputo et al. (2016). Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals. Proc Natl Acad Sci U S A, 113, E4630. PubMed id: 27462106 DOI: 10.1073/pnas.1604463113
Date:
25-Feb-16     Release date:   27-Jul-16    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
Q8BHN3  (GANAB_MOUSE) -  Neutral alpha-glucosidase AB from Mus musculus
Seq:
Struc:
 
Seq:
Struc:
944 a.a.
857 a.a.
Protein chain
Pfam   ArchSchema ?
O08795  (GLU2B_MOUSE) -  Glucosidase 2 subunit beta from Mus musculus
Seq:
Struc:
 
Seq:
Struc:
521 a.a.
88 a.a.
Key:    PfamA domain  Secondary structure

 Enzyme reactions 
   Enzyme class: Chain A: E.C.3.2.1.207  - mannosyl-oligosaccharide alpha-1,3-glucosidase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. N4-(alpha-D-Glc-(1->3)-alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha- D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)- [alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man- (1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein] + H2O = N4-(alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)- alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man- (1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D- GlcNAc-(1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein] + beta-D-glucose
2. N4-(alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha- D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)- alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc- (1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein] + H2O = N4-(alpha-D-Man- (1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D- Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6CC -!- This eukaryotic enzyme cleaves off sequentially the two alpha-1,3-
N(4)-(alpha-D-Glc-(1->3)-alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha- D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)- [alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man- (1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein]
+ H2O
= N(4)-(alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)- alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man- (1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D- GlcNAc-(1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein]
Bound ligand (Het Group name = NAG)
matches with 62.50% similarity
+ beta-D-glucose
N(4)-(alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha- D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)- alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc- (1->4)-beta-D-GlcNAc)-L-asparaginyl-[protein]
+ H2O
= N(4)-(alpha-D-Man- (1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D- Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6CC -!- This eukaryotic enzyme cleaves off sequentially the two alpha-1,3-
Bound ligand (Het Group name = NAG)
matches with 62.50% similarity
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Key reference    
 
 
DOI no: 10.1073/pnas.1604463113 Proc Natl Acad Sci U S A 113:E4630 (2016)
PubMed id: 27462106  
 
 
Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals.
A.T.Caputo, D.S.Alonzi, L.Marti, I.B.Reca, J.L.Kiappes, W.B.Struwe, A.Cross, S.Basu, E.D.Lowe, B.Darlot, A.Santino, P.Roversi, N.Zitzmann.
 
  ABSTRACT  
 
The biosynthesis of enveloped viruses depends heavily on the host cell endoplasmic reticulum (ER) glycoprotein quality control (QC) machinery. This dependency exceeds the dependency of host glycoproteins, offering a window for the targeting of ERQC for the development of broad-spectrum antivirals. We determined small-angle X-ray scattering (SAXS) and crystal structures of the main ERQC enzyme, ER α-glucosidase II (α-GluII; from mouse), alone and in complex with key ligands of its catalytic cycle and antiviral iminosugars, including two that are in clinical trials for the treatment of dengue fever. The SAXS data capture the enzyme's quaternary structure and suggest a conformational rearrangement is needed for the simultaneous binding of a monoglucosylated glycan to both subunits. The X-ray structures with key catalytic cycle intermediates highlight that an insertion between the +1 and +2 subsites contributes to the enzyme's activity and substrate specificity, and reveal that the presence of d-mannose at the +1 subsite renders the acid catalyst less efficient during the cleavage of the monoglucosylated substrate. The complexes with iminosugar antivirals suggest that inhibitors targeting a conserved ring of aromatic residues between the α-GluII +1 and +2 subsites would have increased potency and selectivity, thus providing a template for further rational drug design.
 

 

spacer

spacer